Making an Impact
Only research will spark new discoveries in childhood cancer, leading to clinical trial options for patients today and ultimately, to less-toxic treatments for patients around the world. We know that our volunteers and donors place their trust in us to identify and fund the most innovative research projects while effectively managing expenses to maximize program support.
In 2019, 68% of our expenses were allocated to programs, primarily research grants across all 3 of our funding arms: Young Investigator, Acceleration Initiative, and a $1 million dollar Catapult Award commitment supporting a phase 1 clinical trial for a game-changing new treatment for the deadly brain tumor DIPG. For 2020, we anticipate that our program investment will exceed 70% of total expenses.
We are grateful to the donors, fundraisers, and volunteers who support our shared mission to end children’s cancer, and we are committed to stewarding every dollar raised toward the greatest impact on the children, adolescents, and young adults who are depending on us.
Audited Financial Statements
- Fiscal Year 2020 Audited Financial Statements for period ending 12/31/20
- Fiscal Year 2019 Audited Financial Statements for period ending 12/31/19
- Fiscal Year 2018 Audited Financial Statements for period ending 12/31/18
Federal 990 Tax Forms
- Fiscal Year 2020 Federal Tax Return for period ending 12/31/20
- Fiscal Year 2019 Federal Tax Return for period ending 12/31/19
- Fiscal Year 2018 Federal Tax Return for period ending 12/31/18
GuideStar: CureSearch is a Platinum participant in the GuideStar Exchange program. Participation allows us to update key information directly to GuideStar so it is available to its millions of users on a regular basis. It provides richer and broader information about our programs, impact, finances, people and more. CureSearch has provided evidence of impact, financial data, IRS Forms 990 and our mission objectives.